Archive

Discordance Between Gated Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging and Coronary Angiography in Dilated Cardiomyopathy

In DCM, SPECT-MPI and angiography can disagree on ischaemic versus non-ischaemic aetiology, so don't let a perfusion report alone decide whether a patient needs revascularisation workup.

Cardiology · Cureus · 18 Sept

Underestimation of Low-Density Lipoprotein Cholesterol (LDL-C) Using the Friedewald Equation at Higher Triglyceride Levels: Evidence From a Method-Comparison Study

Mean bias rose to +20.2 mg/dL (-17.0 to 57.5) at TG 250-300 and +26.5 mg/dL (-17.7 to 70.6) above 300 mg/dL; 58.7% and 58.1% respectively were assigned to a lower LDL-C band.

Cardiology · Cureus · 18 Sept

Cardiometabolic Risk Factors, Obesity Phenotypes, and Novel Anthropometric Indices in Patients With Acute Coronary Syndrome: A Hospital-Based Case-Control Study in Central India

BMI was not associated with ACS (Exp(B) 1.208, 95% CI 0.816-1.790, p=0.345). WHtR was (Exp(B) 2.473, 95% CI 1.638-3.732). MUO versus MHNW: OR 3.33, 95% CI 1.10-10.12.

Cardiology · Cureus · 17 Sept

Intravascular Ultrasound-Guided Iliofemoral Venous Stenting: In-Stent Mural Thrombus as a Possible Early Sign of Occult Malignancy

In-stent mural thrombus after iliofemoral venous stenting may signal undiagnosed cancer, so consider malignancy workup when it appears on surveillance imaging.

Cardiology · Cureus · 17 Sept

Oura, Counsel Health join CMS ACCESS model to test whether wearables and AI can improve chronic care at scale

If CMS pays for AI-guided remote monitoring in cardio-kidney-metabolic disease, your chronic-care workflow may shift to wearable-driven data between visits.

Cardiology · Fierce Healthcare · 17 Sept

Longeveron’s phase 2b stem cell flop spurs cost cutting, exploration of ‘all options’

A phase 2b mesenchymal stem cell trial in hypoplastic left heart syndrome missed its endpoint, so don't expect this cell therapy to reach your paediatric cardiac patients soon.

Cardiology · Fierce Biotech · 17 Sept

Tocilizumab in Acute Coronary Syndromes: A Systematic Review of Randomized Controlled Trials

Tocilizumab more than halved CRP area under the curve in three intravenous trials (all p < 0.001); one trial improved myocardial salvage index, but MACE and six-month clinical outcomes did not differ.

Cardiology · Cureus · 16 Sept

Minimally Invasive Coronary Artery Bypass Grafting (MICS-CABG) Versus Conventional Off-Pump Coronary Artery Bypass Grafting (OPCAB): A Single-Center Analysis of Early Outcomes and Institutional Experience

Ventilation was 8.80 ± 3.97 hours with MICS-CABG versus 4.22 ± 2.64 hours with OPCAB; chest drainage 887.0 ± 611.8 mL versus 328.9 ± 116.1 mL. No mortality or sternotomy conversion in either group.

Cardiology · Cureus · 16 Sept

Comparative Outcomes of Beta-Blockers vs Non-Dihydropyridine Calcium Channel Blockers in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis

In HFpEF, beta-blockers and non-dihydropyridine calcium channel blockers show comparable outcomes, so choice can hinge on heart rate, exercise tolerance and tolerability rather than assumed superiority.

Cardiology · Cureus · 16 Sept

Risk-guided cardioprotection in cardio-oncology.

Trials selecting patients by cancer type and treatment regimen show modest to no significant benefit on subclinical or clinical measures of cardiotoxicity; risk-guided selection is proposed but not yet tested

Cardiology · Nature cardiovascular research · 16 Sept

Beyond Prognosis: A Systematic Review of the Neutrophil-to-Lymphocyte Ratio as a Modifiable Cardiovascular Biomarker

IL-6 inhibition gave the clearest dose-dependent NLR reduction; glutathione, cardiac rehabilitation, time-restricted eating, curcumin and hyperoxia also looked favourable. SGLT2 inhibitor results were inconsistent. Clinical outcomes were rarely reported and underpowered.

Cardiology · Cureus · 15 Sept

Age-associated loss of lymphatic vessels promotes cardiac inflammation.

Aging lowered cardiac lymphatic density in humans and mice, with immune infiltration, fibrinogen and amyloid accumulation and myocardial edema; Vegfc overexpression or Il33 silencing restored lymphatic density and homeostasis in aged hearts.

Cardiology · Nature cardiovascular research · 15 Sept

A Synopsis of the 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for Lipid Management for Cardiovascular Disease Risk Reduction.

New: PREVENT calculator for primary prevention risk estimation; routine lipid monitoring no longer discouraged; coronary artery calcium for intermediate-to-high risk with uncertainty; one-time lipoprotein(a) testing; moderate-intensity statins for adults with HIV even at low 10-year risk.

Cardiology · Annals · 15 Sept

Renal Dysfunction and Cardiorenal Syndrome in Acute Heart Failure: A Systematic Review of Residual Congestion and Decongestion Response

Residual congestion was consistently associated with worse clinical outcomes, while worsening renal function during effective decongestion did not uniformly predict adverse renal or cardiovascular events.

Cardiology · Cureus · 14 Sept

Managing Cardiac Amyloidosis in a Rural Cardiology Practice: Bridging Gaps in Specialized Evaluation and Disease-Modifying Treatment

All three patients were effectively evaluated using a streamlined diagnostic pathway and started on disease-modifying therapy promptly, despite limited access to advanced imaging, biopsy and genetic testing

Cardiology · Cureus · 14 Sept

Ischemic Stroke During Rivaroxaban Therapy: The Importance of Food-Dependent Absorption and Careful Assessment Before Antithrombotic Escalation

Before adding an antiplatelet after a stroke on rivaroxaban, check food-dependent absorption and timing — escalation may raise bleeding without fixing the cause.

Cardiology · Cureus · 14 Sept

Integrated Clinical, Biological, and Echocardiographic Factors Independently Associated With In-Hospital Mortality in Infective Endocarditis: A Single-Centre Cohort Study From Morocco

In-hospital mortality was 27.7% (72/260). Independent predictors: septic shock (aOR 28.45; 95% CI 3.42-106.80), vegetation >15 mm (aOR 2.50; 95% CI 1.00-6.20), male sex (aOR 2.68; 95% CI 1.12-6.42), anaemia and severe renal dysfunction.

Cardiology · Cureus · 13 Sept

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Genome Editing in Inherited Cardiovascular Diseases: Therapeutic Advances, Emerging Editing Platforms, and Translational Challenges

No trial results are reported. Preclinical work corrected MYBPC3 and MYH7 in HCM, targeted TTN, RBM20 and LMNA in DCM, restored ion channel function, and modulated PCSK9, LDLR and ANGPTL3.

Cardiology · Cureus · 12 Sept

Polyvascular Atherosclerotic Disease: A Narrative Review of the Role of Systematic Bedside Vascular Examination

No original data or effect estimates are reported; the review argues that abnormal bedside findings should prompt selective ABI, duplex, CTA, MRA or cardiac testing rather than indiscriminate imaging.

Cardiology · Cureus · 11 Sept

ARPA-H launches $63M effort to build FDA-authorized AI agents for heart failure care

Autonomous AI agents for heart failure could soon reach your clinic with FDA oversight, so watch how these tools are validated before adoption.

Cardiology · Fierce Healthcare · 11 Sept

Tricuspid Stenosis Due to Cardiac Sarcoma

Echocardiography showed a large right atrial mass obstructing tricuspid inflow plus significant pericardial effusion; resection confirmed biphasic synovial sarcoma. Postoperatively he developed atrial flutter with left ventricular dysfunction needing cardioversion.

Cardiology · Cureus · 11 Sept

STAT+: An AI tool aims to catch harder-to-detect heart attacks in EKGs

An AI ECG reader cleared to flag occult coronary occlusion could catch NSTEMI and posterior MI patterns that clinicians and standard algorithms miss.

Cardiology · STAT News — Health Tech · 11 Sept

Simultaneous derivation, validation, and comparison of predictor hazard ratios for cardiovascular risk prediction equations in patients with diabetes from high versus non-high income countries: cohort study.

Age hazard ratio per 10 years in women was 1.61 (1.51 to 1.71) in New Zealand versus 2.51 (2.32 to 2.72) in China. Recalibration alone left expected-to-observed ratios of 0.938 in men and 0.809 in women.

Cardiology · BMJ · 11 Sept

Right Coronary Artery Thrombosis Causing ST-Elevation Myocardial Infarction After a Coronary Artery Disease Reporting and Data System Score of 0, With Disseminated Intravascular Coagulation During Idiopathic Acute Pancreatitis: A Case Report

A 99% thrombotic subtotal occlusion of the mid-right coronary artery caused inferior STEMI; coronary CT angiography five months earlier had shown an Agatston score of 0 and CAD-RADS 0.

Cardiology · Cureus · 10 Sept

Temporary Left Ventricular Unloading With Impella as a Bridge to Emergency Surgery for Acute Mitral Bioprosthetic Failure

Cardiac index and mixed venous oxygen saturation rose and oxygenation held on less inspired oxygen; mean pulmonary artery pressure stayed around 40 mmHg and did not keep climbing

Cardiology · Cureus · 10 Sept

STAT+: ARPA-H to invest $62 million to develop FDA-authorized AI to help treat heart failure

AI-guided heart failure therapy could soon be FDA-authorized, potentially changing how you titrate medications and monitor patients.

Cardiology · STAT News — Health Tech · 9 Sept

Abbott garners FDA nod for its TactiFlex catheter to treat AFib

A new ablation catheter option for AFib may improve procedural flexibility and outcomes in your electrophysiology cases.

Cardiology · Fierce Biotech · 9 Sept

Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial.

Mitiperstat (pooled doses) did not improve KCCQ-TSS (placebo-corrected difference -1.4 points, 95% CI -3.9 to 1.2; P=0.29) or 6MWD (3.8 m, 95% CI -3.1 to 10.8; P=0.28) or any secondary endpoint.

Cardiology · Nature Medicine · 9 Sept

Ranolazine in Chronic Stable Angina: A Systematic Review and Meta-Analysis

Exercise duration increased by 33.1 seconds (95% CI 27.3-38.9). MI risk reduced (RR 0.91; 95% CI 0.84-0.98), CABG (RR 0.55; 95% CI 0.35-0.86), any revascularization (RR 0.77; 95% CI 0.64-0.91). Adverse events more frequent (RR 1.45; 95% CI 1.27-1.66).

Cardiology · Cureus · 7 Sept

Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial

Despite lowering Lp(a), this drug did not cut heart attack or stroke risk—so don't start checking Lp(a) routinely yet.

Cardiology · Fierce Biotech · 5 Sept

Dapagliflozin and Risk of Perioperative Acute Kidney Injury in Cardiac Surgery

Perioperative AKI after cardiac surgery is common; this trial tests whether continuing SGLT2 inhibitors changes that risk, informing your pre-op medication decisions.

Cardiology · JAMA · 1 Sept

SGLT2 Inhibitors for Prevention of AKI

Starting dapagliflozin the day before elective cardiac surgery may cut postoperative AKI—consider timing and renal risk in your surgical patients.

Cardiology · JAMA · 1 Sept

Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery Research Summary

If dapagliflozin cuts post-op AKI, you can start it pre-surgery to protect kidneys in high-risk cardiac patients.

Cardiology · JAMA · 1 Sept

Boston Scientific halts sales of angiographic catheters amid 2 serious injuries

Check your stock of Imager II catheters; tip defect may cause serious injury—stop use and follow recall instructions.

Cardiology · Fierce Biotech · 1 Sept

ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CM

For cardiologists managing ATTR-CM, this suggests RNAi may still benefit patients on tafamidis despite the Wainua failure—watch for confirmatory data.

Cardiology · Fierce Biotech · 31 Aug

ESC26: AstraZeneca's heart failure drug shows promise in ph. 2 trial

Oral relaxin agonist improved cardiac function in chronic heart failure—watch for a potential new add-on beyond standard therapy.

Cardiology · Fierce Biotech · 31 Aug

Targeted left ventricular lead placement in biventricular pacing for heart failure: a national, multicentre, double-blind, randomised controlled trial in Denmark.

Primary endpoint occurred in 139/499 (28%) intervention vs 128/501 (26%) control (HR 1.10, 95% CI 0.86-1.39; p=0.45). No benefit.

Cardiology · Lancet · 31 Aug

Catheter-Directed Thrombolysis in Intermediate-High-Risk Pulmonary Embolism.

Primary composite event occurred in 2/280 (0.7%) thrombolysis vs 19/278 (6.8%) standard care (RR 0.10, 95% CI 0.02-0.44, P<0.001), driven by reduced cardiorespiratory decompensation. Major bleeding 1.4% vs 2.2% (P=0.54).

Cardiology · NEJM · 31 Aug

Short-term effects of combinations of heart failure therapies on blood pressure, kidney function and serum potassium.

In HFrEF, ARNI+SGLT2i+sMRA reduced SBP by -9.2 (-10.6 to -7.8) mmHg, eGFR by -6.8 (-7.9 to -5.4) ml/min/m2, increased potassium by +0.30 (0.25-0.35) mmol/l. In HFmrEF/HFpEF, SGLT2i+sMRA reduced SBP -5.9 (-7.3 to -4.6) mmHg, eGFR -7.7 (-8.9 to -6.4), potassium +0.34 (0.29-0.38).

Cardiology · Nature Medicine · 31 Aug

FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol

Offers an oral alternative to injectable PCSK9 inhibitors, potentially improving adherence for your high-cholesterol patients who avoid injections.

Cardiology · FDA — Press Announcements · 17 Jul